"Lead, follow, or get out of the way."
This is one of those well-known aphorisms that's been around forever – though its originator is unknown.
Truth be told, it doesn't matter who said it first. It's a great bit of advice.
Especially as we interpret it.
In our investment work here at Money Morning, we always seek to lead Wall Street and the rest of the packrat investment crowd.
We never follow, especially since "the crowd" tends to be indecisive, late to the gun – or flat out wrong.
And we always get out of the way – sidestepping the dust-rising thump that's an inevitable result of the miscues and sins of the Wall Street Goliath.
It's a simple formula. And a successful one.
And it's the reason we keep outperforming "the crowd."
Like the 2,067% gain on biotech Galapagos NV, the very first stock I recommended on the very first day I published my Member-based service, Private Briefing, back in August 2011.
My readers also pulled down peak gains of more than 2,892% in Nvidia, 2,828% in Advanced Micro Devices, 818% in biotech buyout Pharmacyclics, and more.
Today, I've decided to share my latest insight on one of my big biotech winners with Money Morning readers because the opportunity is too good to keep to ourselves. And since my colleague Michael Robinson recently talked about 2020's record-crushing biotech IPOs, it's the perfect time to share this.
The company I'm showing you today is essential to biotech stocks. It's a "biotech-enabler" that's zoomed 1,755% since I first told my readers about it back in June 2013.
In 2013, it was trading at $8.14.
It closed July 30 at $151.25 – not long after Investor's Business Daily said the stock had entered a "Buy Zone."
True, but where were they seven years and 1,755% ago?
Of course, what's important now is what comes next – and it's clear this stock's run isn't over… Full Story